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In human beings, as well as in most non-human primates, the major peripheral γδ T cell
subset, which accounts several percent of the whole lymphoid cells pool in adults, carries
an heterodimeric TCR composed of Vγ9 and Vδ2 chains. Vγ9Vδ2 T cells are specifically
and strongly activated by small organic pyrophosphate molecules termed phosphoanti-
gens (phosphoAg). These low molecular weight compounds are metabolites that are
produced by either microbes or endogenously, as intermediates of the mammalian meval-
onate pathway, and can accumulate intracellularly during cell stress like transformation
or infection. Despite the characterization of numerous natural and synthetic phosphoAg,
the mechanism(s) underlying the unique and specific antigenic activation process induced
by these compounds remains poorly understood. Activation is both TCR- and cell-to-cell
contact-dependent, and results of previous studies have also strongly suggested a key
contribution of membrane-associated molecules of primate origin expressed on target
cells. The recent identification of B7-related butyrophilin (BTN) molecules CD277/BTN3A,
and more precisely their BTN3A1 isoforms, as mandatory molecules in the phosphoAg-
induced recognition of target cells by Vγ9Vδ2 T cells opens important opportunities for
research and applications in this field. Here, we review the unusual and complex antigenic
reactivity of human Vγ9Vδ2 T cells. We highlight the recent advances in our understanding
of this process, and propose a model that integrates the type I glycoprotein BTN3A1 and
its intracellular B30.2 domain as a physical intermediate implicated in the detection of dys-
regulated intracellular levels of phosphoAg and the sensing of cell stress by Vγ9Vδ2T cells.
A better understanding of this mechanism will help optimize novel immunotherapeutical
approaches that utilize the unique functional potential of this major γδT cell subset.
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γδ T CELLS AS MANDATORY T CELL SUBSETS OR
EVOLUTIONARY RELICS?
T cells are critical component of the adaptive immune system
and are essential for defense against foreign organisms and self-
dysregulation. T cells can be divided into two lineages, according
to the composition of their T cell receptor (TCR). While most αβ
T cells recognize peptidic antigens (Ag) bound to highly polymor-
phic major histocompatibility complex (MHC) molecules and are
qualified as conventional T cells, several T cell subsets react against
conserved non-peptidic Ag. Like other adaptive immune effectors,
these latter non-conventional or innate-like T cells express clon-
ally distributed Ag recognition receptors, made of either αβ or
γδ TCR subunits, which are associated to subunits of the CD3
signal transduction complex at the cell membrane. The onto-
genic and developmental features of γδ T cells, which have been
extensively reviewed elsewhere (1–4), will be summarized here.
During thymic ontogeny, γδ T cells emerge before αβ T cells
and are predominant at early stages of fetal development (embry-
onic days from 14 to 18 in mice). One of the striking hallmarks
that distinguish γδ from αβ T cell subsets is their potential for
TCR structural diversity, which is considerable despite a highly
restricted V gene repertoire. However, this very limited com-
binatorial diversity of γδ TCR is efficiently counterbalanced by
extensive junctional diversity, due to removal or addition of non-
germline-encoded nucleotides at V-(D)-J junctions and alternate
D segments reading frames, which allows the generation of a γδ
TCR diversity greater than that of conventional αβT cells (theoret-
ically ~1016 in rodents and human). The extent of TCR junctional
diversity can greatly vary from one γδT cell subset to another, with
several populations expressing highly conserved so-called “invari-
ant” TCRs in some tissue locations, as it is the case for murine
Vγ5Vδ1 or Vγ6Vδ1 T cell subsets. An important feature of γδ T
cells is the preferential expression of TCR V regions in distinct tis-
sue locations. In human beings, Vγ9Vδ2 T cells are preferentially
found in the peripheral blood where they represent more than
80% of γδ T cell pool, and about 5% of the CD3+ cells in healthy
adults. By contrast, Vδ2− subsets, such as Vδ1+ and Vδ3+ sub-
sets, are mainly detected in epithelial tissues (e.g., epidermis and
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mucosa), spleen, thymus, and liver. The preferential localization
of γδ T cell subsets might be explained by their capacity to be acti-
vated and to expand upon recognition of specific ligands whose
expression would be restricted to particular tissues, or to specific
homing capacities acquired during intrathymic development (5).
In agreement with a peripheral tissue expansion process, absolute
numbers of human Vγ9Vδ2 T cells steadily increase in blood dur-
ing the first years of life as the diversity of their TCR repertoire
decreases.
Strikingly and in contrast to mice and humans, γδ T cells often
represent the major circulating lymphocytes in cattle, sheep, pigs,
and birds (6), which strengthen the idea that γδ T cells play a criti-
cal role in immune responses to cell stress and infections. However,
since the initial characterization of γδ T cells in the late 1980s, the
raison d’être of this mysteriously distinct subset of CD3+ T cells
within evolved vertebrate species (such as primates and rodents),
which already carry innate and adaptive immunity cell subsets,
remains unclear. A recent study has revealed that the genetic pro-
grams for two primordial T cell-like lineages, oddly similar to
αβ and γδ T cells, and one B cell-like lineage are found in sev-
eral species of jawless vertebrates devoid of RAG recombinase and
MHC molecules (7). It is not known whether a tripartite adap-
tive immune system was already present in a common vertebrate
ancestor 500 millions years ago, and diverged since then along two
distinct phylogenetic lineages, or it appeared two times indepen-
dently by convergent evolution. Yet this finding strongly argues for
a unique role of γδ T cells, as effectors of the transitional immu-
nity endowed of unique functional properties and/or antigenic
specificities.
FUNCTIONAL FEATURES AND ANTIGENIC SPECIFICITIES OF
γδ T CELLS
γδT cells have been characterized for their ability to deliver a broad
array of effector functions upon activation in vitro and in vivo.
Numerous studies mostly performed in mice, human beings, and
non-human primates, indicate that γδ T cells are implicated in the
control of infectious (e.g., bacteria, virus, parasite) diseases, tumor
development, homeostasis, wound healing, and tissue repair. The
functional features of γδ T cells have been recently and extensively
reviewed elsewhere (3, 4, 8) and will not be detailed in this review.
γδT cells, including human Vγ9Vδ2 T cells, can directly kill and
eliminate infected, activated, or transformed cells and contribute
to pathogen clearance. In these physiopathological contexts, acti-
vated γδ T cells engage pathways associated to the release of cyto-
toxic and bacteriostatic molecules such as perforin, granzymes,
granulysin, and defensins, death-inducing receptors and TNF-
related apoptosis-inducing ligand receptors. γδ T cells are also
able to produce modulatory cytokines that play a key role against
intracellular pathogens and the promotion of inflammation (e.g.,
TNF-α, IFN-γ), extracellular bacteria, fungi (e.g., IL-17), and par-
asites (e.g., IL-4, IL-5, IL-13). γδ T cell-released cytokines and
factors might have beneficial or deleterious effects according to
the physiopathological context. As an example, activated γδ T
cells are able to downmodulate immune responses (e.g., TGF-β,
IL-10), to promote tissue healing, epithelia repair, and cell sur-
vival. Interestingly, studies have shown that activated γδ T cells
can promote dendritic cells (DC) maturation through the release
of type I and type II IFNs, which underlies their adjuvant role
played for the control of infections (9–12). Unexpectedly, some γδ
T cell subsets, like human Vγ9Vδ2 T cells, could also constitute
a novel type of professional APC that would elicit CD8+/CD4+
αβ T cell responses through the acquisition of a DC-like pheno-
type upon antigenic activation (13). Whether or not such function
is found in other human and murine γδ T cell subsets remains
to be assessed. To date, none of the broad functional features
described for γδ T cells is specific to this T cell subset. Conju-
gated attempts of many laboratories failed to clearly establish and
define common functional features of γδ T cells that would basi-
cally distinguish them from conventional and innate-like αβ T
cells. Taken together, these observations suggest that most of the
key contribution of the functional responses displayed by acti-
vated γδ T cells might rather rely on the tight regulation of their
kinetics of activation as well as the ability of these innate-like T
cell subsets to be present “at the right time, in the right place.”
The unique Ag specificities of γδ T cells could also significantly
account for their “programed” distribution within organs and tis-
sues and their striking evolutionary conservation aside from T and
B cell subsets which also assemble their Ag-receptor genes through
recombinatorial rearrangement.
One particularly attractive hypothesis to account for the
remarkable species and inter-individual conservation of γδ T cells,
as well as the lack of functional redundancy with αβ T and B cells,
is that this former subset, like an intermediate “T–B hybrid” cell
type, might be rather designed for an efficient and unique mode
of recognition of a broad set of conserved native Ag (e.g., pro-
teins, lipids, carbohydrates) or complexes. In such contexts, this
set of Ag either directly interact with γδ TCR or are presented
by non-polymorphic MHC-related or yet unknown presenting
molecules. In line with this hypothesis, the structure of γδ TCR
heterodimers suggests that these molecules display immunoglob-
ulin (Ig)-like recognition features, which strengthen the idea for
alternative modes of Ag recognition by γδ TCRs (14). This view is
supported by both the diversity and the nature of γδ TCR agonist
molecules already identified, as well as by the direct reactivity of
γδ T cells and B cells against similar native molecules (e.g., F0-F1
ATP synthase, phycoerythrin) (15, 16).
γδ T cells are key players in the immune surveillance of cellular
distress, owing to their general ability to recognize Self deter-
minants that are frequently upregulated in contexts of inflam-
mation, infection, or cancer. While γδ TCR contribute to detec-
tion of danger-associated molecular patterns, cognate interactions
between γδ TCR and defined Ag have been reported in a few cases
only. As for some other innate-like cell subsets, γδ T cells can be
activated, in a cell-to-cell contact but classical MHC-independent
manner, by small molecules or intact proteins without require-
ment for a processing similar to the conventional αβ T cells Ag.
Strikingly, while γδ T cells can respond to different stimuli in
various physiopathological contexts, a substantial fraction of the
physiological murine and human γδ TCR ligands characterized so
far fall into the large MHC class I-related molecules family (e.g.,
T10-T22, MICA/B, CD1c, CD1d, EPCR) (17–21). Moreover the
activation of γδ T cells subsets by some of these molecules might
be dependent on their ability to present specific ligands such as
lipids (e.g., EPCR, CD1d).
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THE HISTORY OF PHOSPHOANTIGENS AND THE FIRST
IDENTIFICATION OF NATURAL HUMAN Vγ9Vδ2 T CELL
AGONIST MOLECULES
In humans, as well as in most non-human primates, the major
peripheral γδ T cell subset in adults carries a TCR composed
of a Vδ2 chain systematically paired to a Vγ9 chain (using the
nomenclature of Lefranc and Rabbitts (22), also referred to as
Vγ2 by using the Seidman and colleagues nomenclature). This γδ
T cell subset represents about 5% of CD3+ cells within human
peripheral blood and more than 80% of the peripheral γδ T
cell population in healthy adults. After the fortuitous discov-
ery of γδ T cells and the subsequent generation of monoclonal
antibodies (mAbs) specific for human γ or δ TCR chains, high
frequencies of Vγ9Vδ2 T cells were reported within peripheral
blood or lesions from patients infected by a variety of bacte-
ria (e.g., Mycobacterium leprae, Mycobacterium tuberculosis) and
protozoans. Accordingly, Vγ9Vδ2 T cells efficiently responded
to mycobacterial extracts in vitro, which contained small non-
peptidic compounds (protease-resistant) that also bind to lectins.
The isolation and characterization of the stimulatory fractions
within these extracts led to the identification of various agonist
low molecular weight carbohydrate compounds that were struc-
turally related to phosphoesters and depend on the presence of
phosphate moieties for their bioactivity (23–26). IPP (isopen-
tenyl pyrophosphate) from M. smegmatis was identified as the
first natural agonist for Vγ9Vδ2 T cells. This compound, and its
isomer DMAPP (dimethylallyl pyrophosphate), were called phos-
phoAg, a family of compounds including the E coli and mycobacte-
ria-derived (2E)-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate
(HDMAPP), also known as (E)-4-hydroxy-3-methyl-2-butenyl
pyrophosphate (HMBPP), and additional natural molecules pro-
duced by many microorganisms and plants (27–30) (Figure 1).
Reports also indicated that Vγ9Vδ2 T cells are efficiently activated
by a broad array of human tumor cells, such as lymphoma and car-
cinoma. The Vγ9Vδ2 T cells antigenic molecules from tumor cells
were identified as IPP and DMAPP phosphorylated metabolites of
the isoprenoid mevalonate (MVA) biosynthesis pathway, which is
implicated in cholesterol synthesis (31). Accordingly, pharmaco-
logical MVA pathway inhibitors acting upstream (e.g., statins) or
downstream (e.g., alkylamines; aminobisphosphonates, NBP) of
phosphoAg biosynthesis, respectively, decrease or increase Vγ9Vδ2
T cell activation (32). Whereas most eukaryotic cells, fungi and
archeabacteria produce isoprenoids through the MVA pathway,
most of eubacteria, cyanobacteria, and algae protozoa synthesize
isoprenoids through a related biosynthesis pathway referred to as
the 1-deoxy-d-xylulose-5-phosphate (DOXP) or 2-C-methyl-d-
erythritol 4-phosphate (MEP) pathway (33). HDMAPP produced
through the DOXP pathway remains the most potent natural
Vγ9Vδ2 activator so far identified (bioactivity of 0.1 nM, which is
30,000 times more potent than IPP). This suggests that this highly
potent microbial phosphoAg, rather than endogenous phosphoAg
such as IPP, would account for the highly sensitive sensing by
Vγ9Vδ2 T cells of infected cells or pathogens using the DOXP/MEP
pathway. The efficiency of the microorganisms recognition process
by γδ T cells was linked to their DOXP/MEP isoprenoid synthe-
sis pathway (34). Accordingly, the genetic manipulation of the
DOXP/MEP pathway in bacteria, similarly to the pharmacologic
FIGURE 1 | Examples of characterized phosphoantigens that induce
Vγ9Vδ2 T cell activation. These listed phosphoAg are either from natural
or synthetic origin. They induce different range of activation with EC50 value
for Vγ9Vδ2 T cell activation that can vary between different human donors.
From Ref. (36, 39, 64, 97).
manipulation of the MVA pathway in human cell lines, regulates
the production of these microbial phosphoAg which resulted in the
modulation of the antigenic activation of Vγ9Vδ2 T cells (34, 35).
Research groups have next attempted to define the chemical
basis and structure-to-functions relationships for the antigenicity
of phosphoAg. These studies first reported that the substitution of
phosphate for the pyrophosphate moiety or the elimination of the
double bond reduced antigenic bioactivity of these compounds
(24). As synthetic phosphoAg have been further produced and
tested (e.g., BrHPP for bromohydrin pyrophosphate), these vari-
ous molecules were compared to the natural ones (Figure 1) and
next classified from an antagonist or weak, medium to a strong
agonist bioactivity on Vγ9Vδ2 T cell activation (27, 36). These
studies indicate that agonist or antagonist bioactivity of these com-
pounds correlates with the extent and kinetics of pyrophosphate
dephosphorylation (also referred to as β-phosphate cleavage) and
alteration of their organic segment. Interestingly, a fast extracel-
lular acidification measured after cell exposure to soluble agonist
phosphoAg was reported (37, 38). As the phosphonate moieties
are less susceptible to chemical or enzymatic hydrolysis than their
corresponding phosphate counterparts, some groups have also
synthesized phosphonate and pyrophosphonate analogs that could
have improved pharmacological properties linked to an increased
stability in biological media (39).
The specific and efficient activation of primate Vγ9Vδ2 T cells
induced by isoprenoid phosphorylated compounds provides an
attractive unified explanation for the unique and broad reactivity
of this T cell subset in infectious and tumor contexts. However, the
mechanism(s) of this highly conserved and uncommon specific
antigenic recognition process by Vγ9Vδ2 T cells has remained
puzzling and ill defined.
www.frontiersin.org January 2015 | Volume 5 | Article 657 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Harly et al. Vγ9Vδ2 T cells antigenic activation
A PECULIAR MODE OF Vγ9Vδ2 T CELL ACTIVATION INDUCED
BY PHOSPHOANTIGENS?
The unique ability of primate Vγ9Vδ2 T cells to specifically sense
very subtle variations of phosphoAg levels in various physiopatho-
logical contexts such as infections and cancer highlighted the
importance of the role played by the Vγ9Vδ2 TCR molecules in
this process. Indeed, correlative studies have initially reported the
specific activation of human T lymphocytes expressing a Vγ9Vδ2
TCR by Daudi Burkitt’s lymphoma cells and mycobacteria (40, 41)
and a direct contribution of germline residues specific to Vγ9,Vδ2,
and JγP elements to this recognition process (42). Altogether, these
studies suggested that the antigenic activation of Vγ9Vδ2 T cells
induced by phosphoAg is mediated by germline-encoded segments
of the γδ TCR. The γδ TCR dependence of phosphoAg-induced
T cell reactivity, also supported by the effects of γδ TCR blocking
mAbs (23, 24, 26), has been finally demonstrated by the results
of Vγ9Vδ2 TCR transfer experiments (43). Indeed, the transfec-
tion of a Vγ9Vδ2 TCR in human Jurkat T cells enabled these
cells to produce IL-2 in response to Daudi human tumor cells,
mycobacterial extract, and soluble phosphoAg. Taken together
with additional observations (44–46), this indicated that expres-
sion of Vγ9Vδ2 TCR is necessary and sufficient for the efficient
sensing of identical, or structurally related, Ag from mycobac-
terial extracts, tumor cells, NBP-sensitized cells and synthetic
soluble phosphoAg. Accordingly, events and signaling pathways
classically triggered in T lymphocytes upon TCR-dependent acti-
vation (e.g., Erk and p38 MAPK pathways) were also reported for
phosphoAg-induced activation of human Vγ9Vδ2 T cells (47–50).
Various mechanisms have been proposed to account for the
Vγ9Vδ2 TCR-dependent sensing of phosphoAg that triggers
strong activation of γδT lymphocytes. In a first hypothesis, soluble
phosphoAg, as fully conserved native molecules, which are released
by microbes or mammalian target cells (e.g., from tumor or NBP-
treated cells) could directly, and specifically, interact with Vγ9Vδ2
TCR heterodimers to trigger γδ T lymphocyte activation. This
process would rely on both the bioactivity and the concentration
of the released compounds. This direct interaction model is sup-
ported by: (i) the 3D structural features of a Vγ9Vδ2 TCR together
with the results of γδ TCR transfer/mutagenesis experiments that
revealed the existence of a putative “binding” groove that could
accommodate small (1–3 kDa) negatively charged phosphoAg (14)
and, (ii) a mandatory role of the junctional region of the TCR γ
chain (51) and the contribution of key conserved residues such as:
lysine residue in the γ chain CDR3 loop, an arginine residue in
CDR2δ, and an aliphatic amino acid residue in CDR3δ (52, 53).
However, all attempts to biophysically or biochemically demon-
strate any direct phosphoAg/Vγ9Vδ2 TCR interactions have failed
so far (14, 54) and additional key observations, such as the cell-
to-cell contact requirement for the activation of Vγ9Vδ2 T cells
by soluble phosphoAg (55, 56) do not favor a direct recognition
process.
THE HUNT FOR UNKNOWN
PHOSPHOANTIGEN-PRESENTING MOLECULE(S)
On the basis of these last observations, non-exclusive molecular
events were proposed to account for the necessity of cell-to-cell
contacts for phosphoAg-induced Vγ9Vδ2 T cell activation, such
as: (i) a “stabilization” of native or modified membrane-bound
phosphoAg on target cells surface that would be required for
protection against degradation by extracellular phosphatases, (ii)
a topological clustering/aggregation of phosphoAg and/or their
co-localization with key membrane-associated molecules (e.g.,
adhesion, NKR) for an efficient cross-link of the γδ TCR.
The critical contribution of species-specific Ag-presenting cells
has been evidenced, meaning that only cell-to-cell contact with
human, and some non-human primate cells, are able to trig-
ger a phosphoAg reactivity of human Vγ9Vδ2 T cells (57, 58).
This restriction indirectly suggested the requirement for species-
specific determinants and, as primate phosphoAg-sensitized cell
lines lose their ability to efficiently activate Vγ9Vδ2 T cells upon
protease treatments, these key surface determinants were charac-
terized as membrane-associated proteins (59). Several adhesion
and costimulation molecules (e.g., ICAM-1, CD166) have been
proposed to account, at least partially, for these requirements (57,
58). However, human Vγ9Vδ2 TCR transfer into murine T cell
lines was shown to be sufficient to trigger phosphoAg reactivity
against human, but not rodent target cells (60, 61) (C. Harly & E.
Scotet, unpublished obervations). Additionally, macaque Vγ9Vδ2
TCR tetramers were shown to bind to human, but not mouse cell
surface upon phosphoAg treatment. In agreement with the con-
tribution and the protein nature of key cell surface determinants,
this binding was abrogated by protease pre-treatments of the target
cells (59). Altogether, these results underlined the critical require-
ments of primate cell membrane-expressed determinants of pro-
tein nature, specifically recognized by Vγ9Vδ2 T cells. The contri-
bution of these unknown molecule(s) was further supported by a
study uncovering the role of all the CDRs of Vγ9Vδ2 TCR in the
recognition of phosphoAg-sensitized cells, thus suggesting a large
contact surface with a putative antigenic complexes/molecules,
and not only small phosphorylated compounds (62). Additionally,
the existence of “phosphoAg-presenting molecules”was supported
by the characterization of photoaffinity prenyl pyrophosphate Ag
(analogs of HMBPP), designed to form covalent bounds with
close proximity molecules after UV-treatment. This study suggests
that such molecules stably associate to broadly distributed, func-
tionally non-polymorphic, and not known Ag-presenting mole-
cule(s) on human target cells and activate Vγ9Vδ2 T cells (63).
At last, the generation and the functional characterization of var-
ious synthetic compounds analogous to phosphoAg has revealed
that some of them were not only unable to efficiently activate
Vγ9Vδ2 T cells, but could specifically interfere with the stimu-
lating activity of phosphoAg (37, 63, 64). Similarly, IPP could
efficiently inhibit the stable association of photoaffinity prenyl
pyrophosphate Ag to primate target cells (63). These observations
could reflect the existence of competition mechanisms established
between phosphoAg (e.g., IPP) and analogs for a limited number
of binding sites on the same unidentified molecule(s) expressed
by target cells.
PhosphoAg recognition has been described to be an extremely
rapid process (~10 s) and is not abrogated by glutaraldehyde fixa-
tion of the target cells (36, 55). In contrast, the antigenic activation
of Vγ9Vδ2 T cells by NBPs or alkylamines is indirect and medi-
ated by the intracellular accumulation of IPP (31, 65, 66). It
remains unclear how intracellular IPP is detected at the cell surface.
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Whether phosphoAg are transported, exported (e.g., intracellular
IPP) outside or internalized inside (e.g., extracellular HMBPP)
the target cells, specifically or not, anchored or adsorbed on target
cell surface, whether they interact with yet unknown ubiquitous
surface molecule or whether they rapidly regulate the expres-
sion/conformational changes of determinants that are detected
by Vγ9Vδ2 TCR remains open.
Taken together, the previous findings would tend to rule out
a “simple” direct recognition process of phosphoAg by Vγ9Vδ2
T cells, and lead to hypothesize the existence of a “phosphoAg-
presenting molecule(s)” of protein nature, ubiquitously expressed
on the surface of primate cells. However, such molecule(s) was
never identified, and, as we will see in the second part of this
review, more recent works strongly suggest an alternative model
for phosphoAg sensing by human Vγ9Vδ2 T cells.
BTN3A1, AN UBIQUITOUS CELL SURFACE-EXPRESSED
HUMAN BUTYROPHILIN MOLECULE, PLAYS A MANDATORY
ROLE FOR THE ACTIVATION OF HUMAN Vγ9Vδ2 T CELLS
INDUCED BY PHOSPHOANTIGENS
Recently, our group has clearly demonstrated for the first time the
specific and mandatory role played by BTN3A1, a type I glycopro-
tein expressed on target cells, in the phosphoAg-induced reactivity
of human Vγ9Vδ2 T cells (60). BTN3A1, -A2, and -A3 constitute
the BTN3A (also known as CD277) subfamily of butyrophilins
(BTN) molecules. These three isoforms are encoded by three dis-
tinct genes, found in human and some non-human primates. Btn
genes constitute a subgroup of at least 10 genes in most species.
Eleven of them have been identified in mouse, and 13 in human,
where they are located in the MHC class I region of chromosome
6p. Notably, BTN family is member of the Ig superfamily and
shares structural homology with B7 family members at extracel-
lular domain level (mostly composed of Ig-like domains referred
to as IgV and IgC domains) (67). Phylogenetically, BTN molecules
share a common ancestor with the B7 family, initially suggesting
that they could have immunological functions (68).
The functions of BTN molecules as well as their molecular
partners remain ill defined. The eponymous BTN gene, BTN1A1,
is highly expressed in the lactating mammary glands (secretory
epithelium) and represents the major protein associated with fat
droplets in milk. BTN1A1 has been reported to mainly play a
role in the regulation of the amount of lipids and size of droplets
expressed in milk of mammals (69). This function is linked to
its intracellular B30.2 domain, which has been shown to bind
xanthine oxydoreductase and stabilize its association with the
milk fat globule membrane (70). A few studies have reported
immunological functions for some human BTN members such as
BTN1A1, BTN2A2 and BTN3A molecules that can regulate cellu-
lar immunity and T/NK cells activation (67, 71–75). As compared
to BNT1A1, human BTN2A and BTN3A are widely expressed
in many tissues (76). The ectodomains of the three isoforms of
BTN3A consist of two domains, so-called IgV and IgC that have
a very high homology (>95%). On the other hand, the intracel-
lular domain B30.2 (PRY/SPRY) is only present in BTN3A1 and
BTN3A3 and poorly conserved. BTN3A1 is ubiquitously expressed
in human beings (75, 77) and homologs are found in all primates
carrying Vγ9Vδ2 T cells (78). Strikingly, BTN3A orthologs are
not found in the rodent lineage, which also lacks Vγ9Vδ2 T cell
counterparts specific for phosphoAg. The emergence of TCR Vγ9,
Vδ2, and BTN3 genes with eutherian placental mammals has been
recently reported (79). This recent study suggests a strong evolu-
tionary functional link between the expression of Vγ9Vδ2 TCR
and BTN3 proteins.
Our study shows a mandatory role for the BTN3A1 isoform
in the specific detection of human distressed cells (e.g., tumor
and mycobacteria infected cells) by human Vγ9Vδ2 T cells, which
strongly suggested that BTN3A1 molecule represent a major
species-specific determinant regulating the antigenic reactivity
of human Vγ9Vδ2 T cells (60). This work demonstrates that
BTN3A1 does not act as a key costimulatory or adhesion mol-
ecule but as a mandatory protein for the Vγ9Vδ2 TCR-dependent
phosphoAg-mediated recognition of target cells. Furthermore, our
data indicate that BTN3A1 expression is necessary for the recog-
nition of human target cells by baboon Vγ9Vδ2 T cells, and that
antigenic activation of baboon Vγ9Vδ2 T cells, induced by either
human or baboon cells is abrogated by a blocking anti-BTN3 mAb
(C. Harly & E. Scotet, unpublished observations), which is fully in
line with the evolutionary functional link between the expres-
sion of Vγ9Vδ2 TCR and BTN3 proteins. It will be interesting
to extend these observations to other Vγ9Vδ2 expressing species,
including the non-primate ones, such as alpacan (79) to either
strengthen or challenge this functional link. Importantly, several
groups (61) (C. Harly & E. Scotet, unpublished obervations) have
reported that the expression of BTN3A1 is probably not sufficient
to induce the recognition of rodent target cells by human Vγ9Vδ2
T cells, even when co-expressed with key human adhesion mol-
ecules (e.g., ICAM-1). In contrast, transferring a 27.4 megabases
region of the human chromosome 6p including BTN3A1 could
confer to a mouse cell line the ability to activate Vγ9Vδ2 T cells in
the presence of phosphoAg (61, 80). This suggests that additional
species-specific partner molecules encoded on the human chro-
mosome 6p, together with BTN3A1, are required for ensuring its
functional activity.
THE INTRACELLULAR B30.2 DOMAIN OF BTN3A1 BINDS
PHOSPHOANTIGENS AND MEDIATES THEIR SENSING BY
Vγ9Vδ2 T CELLS
While other molecules involved in the phosphoAg-mediated
recognition of target cells by Vγ9Vδ2 T lymphocytes remain to be
identified, the physical and chemical features of BTN3A1 already
shed light on possible mechanism(s) taking part to this process.
BTN molecules comprise two extracellular Ig-like domains, a sin-
gle pass transmembrane domain, and, for some members includ-
ing BTN3A1 and BTN3A3, a B30.2 (SPRY/PRY)-related intracel-
lular domain (67). The mandatory role played by BNT3A1 isoform
during antigenic activation of Vγ9Vδ2 T cells, but not BTN3A2
or BTN3A3, first suggested that the highly conserved extracellular
region (>95%) of BTN3A1 unlikely accounts for its functional
specificity in phosphoAg-mediated activation. In line with this
assumption, we next showed, by swapping the domains between
BTN3A isoforms, that the intracellular portion of BTN3A1 is nec-
essary for BTN3A1 to mediate phosphoAg stimulation of Vγ9Vδ2
T cells, and is sufficient to confer this properties to the inactive
isoform BTN3A3 (60). Therefore this finding highlights a crucial
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and specific contribution for the intracellular B30.2 domain of
BTN3A1.
These results have been very recently confirmed and extended
by a joined study from the group of E. J. Adams and ours. In this
work, a set of structural, molecular and cellular approaches has
been performed to unambiguously demonstrate the direct interac-
tion between phosphoAg and the N-terminal part of the intracellu-
lar domain B30.2 of BTN3A1, through a positively charged pocket
(81). Each of the pyrophosphate compound that activate Vγ9Vδ2
T cells bind the B30.2 domain of BTN3A1, but not the B30.2
domain of BTN3A3, and their agonist potency is directly corre-
lated with their binding intensity. Strikingly, comparative sequence
analysis between the B30.2 domains of BTN3A1 and BTN3A3 iso-
forms identified a putative Histidine residue specific to BTN3A1
(replaced by an Arginine at this position in BTN3A3). Struc-
tural, biochemical, and functional assays show that this residue is
required for the binding of phosphoAg to BTN3A1 B30.2,and their
Vγ9Vδ2-stimulating activity. These observations, which have been
confirmed by other groups (64, 82), indicate that internal sensing
of changes in phosphoAg metabolite concentrations by BTN3A1
molecules represent a critical step in Vγ9Vδ2 T cell detection of
infection and tumorigenesis.
PHOSPHOANTIGENS ACT INTRACELLULARLY AND
THEREFORE ARE NOT BONA FIDE Vγ9Vδ2 T CELL ANTIGENS
The direct physical and functional link established between the
intracellular phosphoAg and the transmembrane protein BTN3A1
represents a tremendous advance in deciphering how primate
Vγ9Vδ2 T cells can exquisitely sense the dysregulation of intra-
cellular phosphoAg levels by scanning the surface of distressed
target cells. However, many key issues remain to be solved to fully
understand the fine modalities of this process, summarized in
Figure 2A. How is the intracellular interaction between pyrophos-
phate compounds and intracellular B30.2 domain translated to the
cell surface? Which cell surface determinants are finally detected by
Vγ9Vδ2 T cells? How exogenous phosphoAg efficiently “sensitize”
target cells through BTN3A1, while the negative charge of their
phosphorylated moities unlikely allows them to passively cross the
plasma membrane, and their mode of action was proposed to be
independent of any active processing machinery (55, 63)?
A recent study from the group of G. De Libero has proposed an
attractive model for BTN3A1 function, which would resolve some
of these issues. Endogenous and exogenous phosphoAg would
be directly first loaded on the extracellular portion of BTN3A1
and this complex would next directly interact with the Vγ9Vδ2
TCR (80) (Figure 2B). This study provide molecular and cel-
lular evidences for a direct interaction between phosphoAg, the
extracellular IgV domain of BTN3A1, and the Vγ9Vδ2 TCR there-
fore supporting the appealing assignment of BTN3A1 as a classic
Ag-presenting molecule for pyrophosphate compounds. How-
ever, this model appears to be insufficient to explain several key
experimental observations, such as the specific requirement for
BTN3A1 isoform, but not for the BTN3A2 and BTN3A3, whereas
the extracellular domain of the three proteins is highly homolo-
gous, especially within the area composed of the candidate binding
residues for phosphoAg, which are shared between BTN3A1 and
BTN3A2. More importantly, this model also does not take in
account the mandatory role of the intracellular B30.2 domain of
BTN3A1 in this process. A hypothesis that could reconcile some
of the features seemingly contradictory between these two models
would be that BTN3A1 itself is a transporter molecule, or closely
associated with one. In this model, BTN3A1 would interact with
both intracellular and extracellular phosphoAg through, respec-
tively, its B30.2 domain and its extracellular IgV domain. This
latter one would next serve for the presentation of both type of
phosphoAg to Vγ9Vδ2 T cells (Figure 2C). However, the abil-
ity of the extracellular part of BTN3A1 to bind phosphoAg and
interact with the Vγ9Vδ2 TCR has not been confirmed by either
biochemical or functional analysis (61, 64, 81, 82) (C. Harly & E.
Scotet, unpublished obervations). Taken together, the studies per-
formed so far indicate that phosphoAg-induced sensing of target
cells is mediated by the BTN3A1 intracellular B30.2 domain for
both endogenous and exogenous phosphoAg (Figure 2A). As these
results failed to demonstrate any direct contribution (e.g., inter-
actions) of the extracellular region of BTN3A1 in this process,
they would rather support a model in which phoshoAgs are not
directly recognized by Vγ9Vδ2 T cells, and therefore are not bona
fide Vγ9Vδ2 Ag.
An important issue raised from this assumption concerns the
requirements for the internalization of exogenous phosphoAg
within the cells, through the plasma membrane. Early evidence
did not support the existence of such a process: (i) the negative
charge of phosphoAg does not allow them to passively cross the
plasma membrane, (ii) phosphoAg do not seem to require any
active internalization or processing for triggering Vγ9Vδ2 T cell
activation (55, 63), (iii) the very fast kinetics of Vγ9Vδ2 T cell
activation induced by phosphoAg suggest they are readily active
at the extracellular level (37, 38, 47, 49). The mode of intracellu-
lar action of negatively charged exogenous phosphoAg has been
recently addressed in a cellular approach (64). In this elegant study,
synthetic pro-phosphoAg was designed to allow their passive diffu-
sion through the plasma membrane, in an inactive protected state.
After cleavage of the protective groups by intracellular esterases,
active phosphoAg were released and were unable to leave the
cytoplasm. The results clearly show that these highly bioactive
compounds bind the intracellular domain of BTN3A1. Addition-
ally, the intracellular uptake of pro-phosphoAg was confirmed by
a long-term effect of the pro-drug on target cell sensitization after
washes. Therefore, these results strongly support an unified mode
of action of phosphoAg to trigger Vγ9Vδ2 T cell activation, regard-
less of their endogenous, exogenous, intracellular, and extracellular
origin.
Thus, phosphoAg would act intracellularly in target cells and
their direct interaction with the B30.2 domain of BTN3A1 would
be next sensed by Vγ9Vδ2 T cells. This model, as well as the
alternative ones, relies on the existence and the contribution of
additional molecular player(s), involved in either the uptake of
extracellular phosphoAg, or the release of intracellular phosphoAg
(Figure 2). Whether this process is active or not, phosphoAg-
specific or not, and can impact the quality and the magnitude
of the functional activation of Vγ9Vδ2 T cells remains to be deter-
mined. The identification of yet unknown membrane-associated
transporter molecule(s) should greatly help understanding of the
mode of phosphoAg action.
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FIGURE 2 |Three hypothetical activation mechanisms for the
induction of humanVγ9Vδ2 T cells activation by phosphoantigens.
(A) Hypothesis #1: phosphoAg are produced intracellularly or internalized
by unidentified membrane transporter(s). They interact with the
intracellular B30.2 domain of BTN3A1, which induces non-exclusive key
modifications such as conformational changes of the protein,
modifications of its membrane topology, recruitment/exclusion of
molecular partners. These modifications are then sensed by Vγ9Vδ2 T
cells, leading to their functional activation. (B) Hypothesis #2: Intracellular
phosphoAg are exported from the cell by unidentified membrane
transporter(s). Both extra- and intracellular phosphoAg interact with the
extracellular part of CD277/BTN3A. phosphoAg are presented by the
extracellular IgV domain, as antigenic complexes to the Vγ9Vδ2 TCR, which
leads to γδT cell functional activation. (C) Hypothesis #3: this model
shares mechanisms from both hypothesis #1 and #2 models. Intracellular
phosphoAg interact with the intracellular B30.2 domain of BTN3A1. They
are then exported from the cell by BTN3A1 itself, or a membrane
transporter(s) associated with BTN3A1. Both extra- and intracellular
phosphoAg can then interact with the extracellular IgV domain of BTN3A1
and trigger Vγ9Vδ2 T cell activation.
RE-ORGANIZATION OF CELL SURFACE MOLECULES INDUCED
BY INTERACTIONS BETWEEN PHOSPHOANTIGENS AND THE
BNT3A1 INTRACELLULAR B30.2 DOMAIN?
This model of intracellular detection of phosphoAg raises the key
question of the nature of molecular events implicated in the sens-
ing of this process by Vγ9Vδ2 T cells. This binding of phosphoAg
to the B30.2 domain of BTN3A1 should be somehow “translated”
to the cell surface of target cells, in order to be detected by Vγ9Vδ2
T cells. An interesting clue for deciphering this mechanism comes
from the observation that some mAbs specific of the extracellu-
lar region of BTN3A can precisely mimic the phosphoAg-induced
recognition of target cells by Vγ9Vδ2 T cells (60, 83). Additionally,
some anti-BTN3 mAbs abrogate both phosphoAg- and agonist
anti-BTN3 mAbs-induced recognition of target cells by Vγ9Vδ2 T
cells. This suggests similar mechanisms of sensitization of target
cells induced by both phosphoAg and agonist anti-BTN3 mAbs.
Interestingly, the sensitization of target cells induced by agonist
anti-BTN3 mAbs requires neither the presence of phosphoAg nor
the expression of intracellular B30.2 domain. Accordingly, each
BTN3 isoform, comprising or not a B30.2 domain, was equally
able to trigger the functional activation of Vγ9Vδ2 T cells (60, 82).
The structural analysis of extracellular region of BTN3A1 with
agonist ScFv mAb revealed a ~20 Å displacement as measured
between V domains, induced upon binding of the agonist mAb
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(78). Altogether these observations strongly suggest that agonist
anti-BTN3 mAbs can probably induce some key BTN3A struc-
tural modifications, similar to the effects triggered by phosphoAg.
However, agonist anti-BTN3 mAbs in complex with the extracel-
lular part of BTN3, are neither sufficient to activate Vγ9Vδ2 T
cells when plastic-coated or expressed on the cell surface of rodent
cells, nor able to interact with Vγ9Vδ2 TCR in solution (60, 78,
81). Though still conflicting (61, 80), these results suggest that
the direct recognition of either anti-BTN3 mAbs in complex with
extracellular BTN3 or conformational changes/crosslinking of the
extracellular domain of BTN3 induced after binding of these ago-
nist anti-BTN3 mAbs might not be sufficient to fully account for
the antigenic activation of Vγ9Vδ2 T cells.
Thus, the topological remodeling of some cell surface key deter-
minants, involving the aggregation or the exclusion of specific
membrane proteins likely represents an important step for this
stress-sensing process by Vγ9Vδ2 T cells. This is supported by
recent FRAP (Fluorescence Recovery After Photobleaching ) exper-
iments showing that anti-BTN3 mAbs significantly decreases the
mobility of BTN3A isoforms on the cell surface, regardless of the
composition of their intracellular domain (60, 81). Importantly,
similar effects were observed on human target cells with NBP-
induced intracellular accumulations of phosphoAg, in correlation
with the expression of a functional B30.2 domain. Hence, these
results provide a strong link between the reduced surface mobility
of BTN3A on human target cells and their detection by Vγ9Vδ2 T
cells. The mechanism(s) implicated in such membrane diffusion
alterations and the physiological relevance of these events still need
to be experimentally further addressed. It would be interesting to
determine whether human BTN3A molecules, when expressed on
the cells surface of rodent cells, are also immobilized after phos-
phoAg or anti-BTN3 mAbs treatments, despite the inability of
such cells to trigger functional activation of human Vγ9Vδ2 T
cells. Such experiments should help further understand the link
between BTN3A1 reduced mobility induced by phosphoAg and
Vγ9Vδ2 T cell activation, as well as determine whether some key
primate-specific molecules are required for: (i) translating the
phosphoAg/B30.2 interactions into this reduced BTN3A mobility
process, (ii) BTN3A immobilization itself, or, (iii) Vγ9Vδ2 T cell
activation induced following sensing of this alteration of BTN3A
mobility.
These FRAP experiments present essential evidence that the
simple interaction(s) of small intracellular metabolites, like phos-
phoAg, with the ubiquitously expressed intracellular BTN3A1
B30.2 domain can substantially affect the global topological orga-
nization of this cell surface-expressed type I glycoproteins. The
observation that BTN3A1 B30.2 crystals dissolve upon phos-
phoAg soaking (81) raises the possibility that the interaction(s)
between phosphoAg and this B30.2 domain could result in con-
formational rearrangements leading to this membrane mobility
alterations. This hypothesis is supported by nuclear magnetic res-
onance spectroscopy experiments revealing some major chemical
shift perturbations upon phosphoAg binding in the B30.2 domain,
not only within the B30.2 domain, but also in the upstream
membrane proximal region (64). Therefore, these recent results
open the possibility that such induced conformational changes
could be translated from the intracellular domain of BTN3A1
to its extracellular domain, similarly to the “inside-out” signal-
ing process already observed with integrins (84), and result in a
global cell surface remodeling (Figure 3).
WHICH ARE “REAL” TCR LIGANDS FOR HUMAN Vγ9Vδ2 T
CELLS ?
While a lot of attention has recently been brought onto the mech-
anism(s) linking phosphoAg and BTN3A1, the molecule(s) that
could finally interact with the Vγ9Vδ2 TCR and trigger T cell acti-
vation remain(s) unidentified. It is particularly unclear whether
BTN3A1 is directly recognized, alone or in molecular complexes,
or if this molecule indirectly plays a key role for the recognition of
Vγ9Vδ2 TCR ligand(s) at the target cell surface. Several candidate
molecules have been previously proposed as Vγ9Vδ2 T cells Ag
accounting for the specific recognition of tumor or infected cells,
in various pathological contexts. These candidate molecules were
from bacterial [e.g., GroEL HSPs (85)], SEA (86), viral [e.g., HSV-1
glycoprotein I (87), or Self origin [e.g., F 0–F 1 ATP synthase (15)],
ULBP4 (88), MSH2 (89), HSP60 (90)]. Mitochondrial F 0–F 1 ATP
synthase was a particularly interesting candidate as the ectopic cell
surface expression of this mitochondrial complex was reported on
tumor cells. F 0–F 1 ATP synthase also binds a delipidated form
of apolipoprotein A-I, which is required for optimal Vγ9Vδ2 T
cell activation. Further studies showed the direct recognition of
these molecules by the Vγ9Vδ2 TCR (15), a process that can be
modulated by MHC class I molecules (91). Because F 0–F 1 ATP
synthase was shown to interact with some phosphoAg, this mol-
ecule was proposed as a presenting molecule for phosphoAg (92)
but this property has not been yet confirmed. Interestingly, the
recent characterization of Vγ9Vδ2 T cell subsets amplified in vitro
following contact with M. BCG-infected DCs has shown that only
a subset of phosphoAg-responsive Vγ9Vδ2 T cells were actually
responsive to M. BCG (93). TCR repertoire analysis of this T cell
subset revealed a restricted diversity in Vδ2 CDR3 sequences, as
compared to IPP-reactive Vγ9Vδ2 T cells. This study suggested
that the reactivity of these Vγ9Vδ2 T cell subsets toward M. BCG
could be mediated by non-phosphoAg molecules. Similar obser-
vations were made in pulmonary tuberculosis patients (94). The
specificity of these subsets was next characterized which led to
the identification of new protein/peptides of mycobacterial origin
(e.g., OXYS, DXS2, Rv2272) (94, 95) that can interact with Vγ9Vδ2
TCRs and activate a large fraction of Vγ9Vδ2 T cells isolated from
peripheral blood of tuberculosis infected patients but not γδ T
cells of healthy donors.
Therefore, these recent studies provide attractive evidences
that some Vγ9Vδ2 TCRs might not be designed for the unique
detection of phosphoAg/BTN3A1-linked stress signals. However,
antagonist anti-BTN3 mAbs have been shown to abrogate the
recognition of M. BCG-infected cells (60). Even if this result does
not directly address the esssential requirement for BTN3A1 expres-
sion,and its intracellular B30.2 domain, in the reactivity of Vγ9Vδ2
T cells against M. BCG, it strongly underlines an important func-
tion for this BTN in this process. As the “polyreactivity” of various
Vγ9Vδ2 T cell clones toward various antigenic molecules has not
been determined so far, it is therefore difficult to exclude or include
them in a general model of Vγ9Vδ2 T cell activation by phos-
phoAg. An interesting hypothesis is that each of these Vγ9Vδ2
Frontiers in Immunology | T Cell Biology January 2015 | Volume 5 | Article 657 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Harly et al. Vγ9Vδ2 T cells antigenic activation
FIGURE 3 | Different steps of the activation process of human
Vγ9Vδ2T cells induced by phosphoantigens. All the steps/molecules
colored in red have been identified while the green ones will need to
be confirmed. PhosphoAg (pAgs) accumulate intracellularly as
metabolites of the endogenous mevalonate pathway (MVA) or the
microorganism MEP/DOXP pathway. Exogenous pAg can also be
internalized through yet undefined membrane transporter(s).
PhosphoAg directly interact with the N-terminal portion of the
intracellular B30.2 domain of CD277/BNT3A1. Intracellular partner
molecules could be recruited either by BTN3A1 or by phosphoAg.
Following PhosphoAg/B30.2 interaction, the conformation of BTN3A1
is altered and the cell surface distribution of BTN3A1 together with yet
unknown other molecular partners is modified. These exquisite signals
are sensed by Vγ9Vδ2 T cells, in a TCR-dependent manner, leading to
the functional activation of γδT cells. Whether the Vγ9Vδ2 TCR directly
interacts with BTN3A1 remains unclear.
TCR ligands expressed on the surface of stressed target cells is not
individually detected by Vγ9Vδ2 T cells, but become activator as
part of a complex involving several Vγ9Vδ2 TCR ligands, as sug-
gested by the results from the study reporting the recognition of
the F 0–F 1 ATP synthase/ApoA1 complex (15). In agreement with
this idea, BTN3A1 could regulate the formation or the topology
of Vγ9Vδ2 antigenic complexes on the cell surface.
PHYSIOLOGICAL IMPLICATIONS FOR THE DETECTION OF
BOTH MODIFIED-SELF AND NON-SELF BY Vγ9Vδ2 T CELLS
Vγ9Vδ2 T cells have the ability to discriminate between self and
modified-self, by detecting subtle changes of phosphoAg levels,
due to increased MVA pathway activity and/or uptake of exoge-
nous phosphoAg, within stressed, transformed, or infected target
cells. How Vγ9Vδ2 T cells can make this subtle distinction is not
well understood, but a fine control of such capacities is essen-
tial to avoid any deleterious effect linked to the strong effector
functions of Vγ9Vδ2 T cells (e.g., cytolysis) in case of an inap-
propriate activation. Importantly, as also suggested for other T
cell subsets, the recognition of altered determinants, from either
self or non-self origin, by the TCR complex does not fully reflect
the “true” reactivity of these T lymphocytes and the ability of
these ligands/TCR interactions to trigger functional responses.
Indeed, the TCR-mediated reactivity of Vγ9Vδ2 T cells against
target cells not solely depends on the expression levels of Ag but
also relies on the fine tuning of their activation threshold by
costimulatory/adhesion molecules and activating/inhibitory NK
receptors (47, 57, 58, 96).
The interaction of phosphoAg with the intracellular B30.2
domain of the ubiquitous BTN3A1 molecule, at a 1:1 molar
ratio (64, 81), which would be subsequently translated to the
cell surface, offers a simple option for the quantitative sensing
of endogenous phosphoAg within target cells by Vγ9Vδ2 T cells.
However, the MVA pathway, which produces the endogenous
phosphoAg metabolites (e.g., IPP), is constitutively engaged at
different levels of activity in healthy cells, according to their phys-
iological functions. For example, highly proliferating cells such
as activated proliferating T cells display some metabolic char-
acteristics that are very similar to those of stress-altered cells,
including an upregulated MVA pathway. As several additional
molecular players remain to be identified to fully decipher the
mechanisms of phosphoAg sensing by Vγ9Vδ2 T cells (Figure 3),
the complexity of the currently proposed model already offers
many levels of regulation, such as the expression levels of mol-
ecules regulating phosphoAg/B30.2 interactions and/or BTN3A1
conformational/topological changes, as well as the availability of
BTN3A1 or Vγ9Vδ2 TCR ligands themselves. Therefore, follow-
ing their identification, it will be critical to study the expression
of each of these molecules in both physiological and pathologi-
cal contexts. As an hypothesis, BTN3A isoforms that are devoid
of any phosphoAg-binding B30.2 domain could exert inhibitory
functions by competing with BTN3A1 for the interaction with
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molecular partners (e.g., ectopic F 0–F 1 ATP synthase, ApoA1 or
other TCR ligands). To first test this, the expression levels of the
different isoforms of BTN3A will need to be further measured and
compared, not only in different healthy cell subsets (75) but also
in various altered contexts.
Besides their ability to quantitatively sense variations of
endogenous phosphoAg levels in target cells, Vγ9Vδ2 T cells
also efficiently discriminate between weak agonist phosphoAg
that are produced by the endogenous MVA pathway (e.g., IPP)
and strong agonist ones which are produced by the microor-
ganism DOXP/MEP pathway (e.g., HMBPP). Isothermal titration
calorimetry has shown that the potency of phosphoAg correlates
with their binding affinity for the intracellular B30.2 domain of
BTN3A1 (64, 81). According to biochemical and biophysical stud-
ies, the binding of phosphoAg on the B30.2 domain would rely on
their mandatory phosphate moiety, which interacts with a unique
binding site in the B30.2 domain, and could be modulated by
the nature of their organic solvent (64, 81). It remains unclear
how such binding affinities are in turn quantitatively translated
to the target cell surface and next detected by Vγ9Vδ2 T cells.
One possibility is that the stability of these interactions could
directly impact on the stability of the induced BTN3A1 conforma-
tional/topological changes. Another hypothesis is that phosphoAg
direcly or indirectly recruit partner molecules, according to their
biochemical properties. As the chemical reactivity of phosphoAg
has been reported as a key requirement for Vγ9Vδ2 T cells acti-
vation and the kinetics of the dephosphorylation step correlates
with their bioactivity, the importance of the contribution of this
β-phosphate cleavage step will also need to be further analyzed.
Interestingly, some phosphoAg analogs that are resistant to β-
phosphate cleavage are not only unable to activate Vγ9Vδ2 T
cells but also abrogate their activation induced by phosphoAg
(37). These observations suggest that phosphoAg and their analogs
compete for binding/interacting sites (e.g., B30.2 domain) and that
β-phosphate cleavage is required for an additional step still to be
identified.
CONCLUDING REMARKS
Primate Vγ9Vδ2 T cells are endowed with unique reactivity pat-
terns against a broad range of stressed cell targets, including
infected and tumor cells. This property has been mainly attributed
to a specific recognition of dysregulated phosphoAg in various
pathological contexts, as well as an apparently diversified set of
proteins and peptides of Self and non-Self origins that could
directly interact with the Vγ9Vδ2 TCR. Despite the lack of obvi-
ous common feature between all these antigenic determinants,
several Vγ9Vδ2 TCR ligands of Self origin have been linked to
the cell metabolism, and their expression or localization could
be regulated by transformation or infection. Because metabolic
dysregulation represents a general feature of various cell distress
events, including transformation, infection and injury, the activa-
tion of Vγ9Vδ2 T cells induced by this type of antigenic determi-
nants would represent a unique and efficient strategy allowing the
early detection of many pathological contexts. It will be crucial
in future studies to understand by which mechanisms such mole-
cules of diverse nature and origin can trigger and regulate Vγ9Vδ2
T cell antigenic activation, and whether all these molecules are
recognized individually, or as part of a general mechanism of
detection of distressed-self and non-self, involving phosphoAg,
BTN3A1, and various other molecules yet to be identified. Our
attempts to integrate the results of previous experimental data on
the modalities of Vγ9Vδ2 T cell activation induced by phosphoAg,
highlighted by the recent identification of BTN3A1 as mandatory
player in this process, led to an incomplete, yet already complex
model of phosphoAg sensing by Vγ9Vδ2 T cells. Against all expec-
tations,phosphoAg sensing byVγ9Vδ2 T cells is an indirect process
(Figure 3), involving several intermediate players that remain to
be identified.
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